Breaking News

CureVac Granted Mfg. Authorization for GMP Production Suite

GMP Production Suite scales up capacity for preclinical, clinical and early launch needs for proprietary and partnered programs

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

CureVac AG, a clinical stage biopharmaceutical company in the field of mRNA-based drugs, received manufacturing authorization for clinical trial materials produced under Good Manufacturing Practice (GMP) from the Regierungspräsidium Tübingen (as representative of the European Medicines Agency), for the company’s scaled up GMP III production suite. This license marks CureVac’s third production suite to manufacture at GMP pharmaceutical production. CureVac’s GMP I, II and III production suites are...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters